Tuesday May 21, 2013
Royalty Pharma last night raised its hostile bid for Elan to $12.50 per share.
Thursday May 02, 2013
Royalty Pharma today formally submitted its $11.25 per share bid for Elan to the company's shareholders.
Wednesday April 24, 2013
Elan has reported a net loss from continuing operations of €72.8m for the three months to the end of March.
Monday April 22, 2013
The board of Elan has unanimously rejected a formal bid from Royalty Pharma, saying the offer of $11.25 a share grossly undervalues the company.
Friday April 12, 2013
Elan shareholders have voted overwhelmingly in favour of a $1 billion share buyback scheme announced in February.
Wednesday April 03, 2013
Elan has closed the sale of its 50% stake in multiple sclerosis drug Tysabri.
Wednesday March 06, 2013
Royalty Pharma said today that it was standing by its offer to acquire Elan, which has rejected the approach.
Monday March 04, 2013
Elan has said it will give shareholders 20% of the royalty rights for multiple sclerosis drug Tysabri.
Monday February 25, 2013
Elan shares are higher in Dublin trade today after the news that Royalty Pharma had made an indicative proposal to acquire the company.
Friday February 22, 2013
Pharmaceutical company Elan said it will return $1 billion of the proceeds from selling its stake in the multiple sclerosis treatment Tysabri to shareholders.